# US 9,266,952 B2 · Antibodies against ROR1 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,266,952 B2
- Document ID: US9266952B2
- Status: Granted
- Kind: B2
- Application number: 13/992,704
- Filed: 2011-12-12
- Published: 2013-10-24
- Granted: 2016-02-23
- Earliest claimed: 2010-12-10
- Assignees: Kancera AB
- Applicants: Ingrid Teige
- Inventors: Ingrid Teige
- Web page: https://patentgrep.com/patent/US9266952B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to antibodies for inducing cell death by the specific binding of (ROR1), domains thereof or nucleotide molecules encoding (ROR1). There are also provided methods involving and uses of the antibodies of the invention.

## Claims

### Claim 1

An anti-ROR1 antibody comprising a combination of all six CDR regions having the following amino acid sequences:
(a) CDRH1, SEQ ID NO: 57; CDRH2, SEQ ID NO: 58; CDRH3, SEQ ID NO: 59, CDRL1, SEQ ID NO: 60; CDRL2, SEQ ID NO: 61; and CDRL3, SEQ ID NO: 62;
(b) CDRH1, SEQ ID NO: 63; CDRH2, SEQ ID NO: 64; CDRH3, SEQ ID NO: 65, CDRL1, SEQ ID NO: 66; CDRL2, SEQ ID NO: 67; and CDRL3, SEQ ID NO: 68;
(c) CDRH1, SEQ ID NO: 69; CDRH2, SEQ ID NO: 70; CDRH3, SEQ ID NO: 71, CDRL1, SEQ ID NO: 72; CDRL2, SEQ ID NO: 73; and CDRL3, SEQ ID NO: 74;
(d) CDRH1, SEQ ID NO: 75; CDRH2, SEQ ID NO: 76; CDRH3, SEQ ID NO: 77, CDRL1, SEQ ID NO: 78; CDRL2, SEQ ID NO: 79; and CDRL3, SEQ ID NO: 80;
(e) CDRH1, SEQ ID NO: 81; CDRH2, SEQ ID NO: 82; CDRH3, SEQ ID NO: 83, CDRL1, SEQ ID NO: 84; CDRL2, SEQ ID NO: 85; and CDRL3, SEQ ID NO: 86;
(f) CDRH1, SEQ ID NO: 87; CDRH2, SEQ ID NO: 88; CDRH3, SEQ ID NO: 89, CDRL1, SEQ ID NO: 90; CDRL2, SEQ ID NO: 91; and CDRL3, SEQ ID NO: 92;
(g) CDRH1, SEQ ID NO: 93; CDRH2, SEQ ID NO: 94; CDRH3, SEQ ID NO: 95, CDRL1, SEQ ID NO: 96; CDRL2, SEQ ID NO: 97; and CDRL3, SEQ ID NO: 98;
(h) CDRH1, SEQ ID NO: 99; CDRH2, SEQ ID NO: 100; CDRH3, SEQ ID NO: 101, CDRL1, SEQ ID NO: 102; CDRL2, SEQ ID NO: 103; and CDRL3, SEQ ID NO: 104;
(i) CDRH1, SEQ ID NO: 105; CDRH2, SEQ ID NO: 106; CDRH3, SEQ ID NO: 107, CDRL1, SEQ ID NO: 108; CDRL2, SEQ ID NO: 109; and CDRL3, SEQ ID NO: 110;
(j) CDRH1, SEQ ID NO: 111; CDRH2, SEQ ID NO: 112; CDRH3, SEQ ID NO: 113, CDRL1, SEQ ID NO: 114; CDRL2, SEQ ID NO: 115; and CDRL3, SEQ ID NO: 116;
(k) CDRH1, SEQ ID NO: 117; CDRH2, SEQ ID NO: 118; CDRH3, SEQ ID NO: 119, CDRL1, SEQ ID NO: 120; CDRL2, SEQ ID NO: 121; and CDRL3, SEQ ID NO: 122;
(l) CDRH1, SEQ ID NO: 123; CDRH2, SEQ ID NO: 124; CDRH3, SEQ ID NO: 125, CDRL1, SEQ ID NO: 126; CDRL2, SEQ ID NO: 127; and CDRL3, SEQ ID NO: 128; or
(m) CDRH1, SEQ ID NO: 129; CDRH2, SEQ ID NO: 130; CDRH3, SEQ ID NO: 131, CDRL1, SEQ ID NO: 132; CDRL2, SEQ ID NO: 133; and CDRL3, SEQ ID NO: 134.

### Claim 2 (depends on 1)

An antibody as claimed in claim 1 comprising the combination of VH and VL region amino acid sequences of:
SEQ ID NO: 5 and SEQ ID NO: 6,
SEQ ID NO: 7 and SEQ ID NO: 8,
SEQ ID NO: 9 and SEQ ID NO: 10,
SEQ ID NO: 11 and SEQ ID NO: 12,
SEQ ID NO: 13 and SEQ ID NO: 14,
SEQ ID NO: 15 and SEQ ID NO: 16,
SEQ ID NO: 17 and SEQ ID NO: 18,
SEQ ID NO: 19 and SEQ ID NO: 20,
SEQ ID NO: 21 and SEQ ID NO: 22,
SEQ ID NO: 23 and SEQ ID NO: 24,
SEQ ID NO: 25 and SEQ ID NO: 26,
SEQ ID NO: 27 and SEQ ID NO: 28, or
SEQ ID NO: 29 and SEQ ID NO: 30, respectively.

### Claim 3 (depends on 1, 2)

An antibody as claimed in any of claims 1 to 2 comprising the constant region CH, having the amino acid sequence of SEQ ID NO: 3 and the constant region CL having the amino acid sequence of SEQ ID NO: 4.

### Claim 4 (depends on 1, 2)

A pharmaceutical composition comprising an antibody as defined in claim 1 or 2 and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 5 (depends on 1, 2)

A kit of parts comprising:
(i) an antibody as claimed in claim 1 or 2;
(ii) apparatus for administering the antibody; and
(iii) instructions for use.

### Claim 6 (depends on 4)

A kit of parts comprising:
(i) a pharmaceutical composition as claimed in claim 4;
(ii) apparatus for administering the pharmaceutical composition; and
(iii) instructions for use.
